Sanofi to invest 170 million euros in French facility, boosting production of VaxigripTetra influenza vaccine

Sanofi announced Thursday that it will invest 170 million euros ($202 million) to expand its manufacturing site in Val de Reuil, France, boosting production of the influenza vaccine VaxigripTetra. The company said that it plans to complete the expansion by 2021, and will begin producing vaccines in this new facility in 2022.

According to Sanofi, the facility will allow the company to expand supply of VaxigripTetra to up to 70 countries in six continents. The quadrivalent influenza vaccine, which contains two A strains and two B strains of influenza virus, gained approval in Europe last year. The product is indicated for adults and children from 3 years and older, and is already available in 20 European markets.

FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

"This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions," remarked Philippe Luscan, executive vice president of global industrial affairs at Sanofi. Luscan added "our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets."

To read more Top Story articles, click here.